Scalper1 News
Big pharma Bristol-Myers Squibb (BMY) reported good midstage trial results for its drug candidate Opdivo in advanced squamous-cell lung cancer, sending its stock up nearly 8% to a 13-year high in early trading in the stock market today. The company released the abstract summarizing its Friday presentation at the Chicago Multidisciplinary Symposium on Thoracic Oncology, describing results of the Checkmate-063 trial. The patients in the trial were Scalper1 News
Scalper1 News